Skip to main content

Articles

Page 34 of 62

  1. Haptoglobin (Hp) functions as an antioxidant by binding with haemoglobin. We investigated whether serum Hp has a causal effect on macroangiopathy via Mendelian randomization (MR) analysis with common variants ...

    Authors: Shiyun Wang, Jie Wang, Rong Zhang, Tao Wang, Dandan Yan, Zhen He, Feng Jiang, Cheng Hu and Weiping Jia
    Citation: Cardiovascular Diabetology 2018 17:14
  2. Measurement of systolic and diastolic function in animal models is challenging by conventional non-invasive methods. Therefore, we aimed at comparing speckle-tracking echocardiography (STE)-derived parameters ...

    Authors: Csaba Mátyás, Attila Kovács, Balázs Tamás Németh, Attila Oláh, Szilveszter Braun, Márton Tokodi, Bálint András Barta, Kálmán Benke, Mihály Ruppert, Bálint Károly Lakatos, Béla Merkely and Tamás Radovits
    Citation: Cardiovascular Diabetology 2018 17:13
  3. The distribution of glucose and fatty-acid transporters in the heart is crucial for energy consecution and myocardial function. In this sense, the glucagon-like peptide-1 (GLP-1) enhancer, sitagliptin, improve...

    Authors: E. Ramírez, B. Picatoste, A. González-Bris, M. Oteo, F. Cruz, A. Caro-Vadillo, J. Egido, J. Tuñón, M. A. Morcillo and Ó. Lorenzo
    Citation: Cardiovascular Diabetology 2018 17:12
  4. Albuminuria is of one the strongest predictors of cardiovascular disease (CVD) in diabetes. Diabetes is associated with cardiac microvascular dysfunction (CMD), a powerful, independent prognostic factor for ca...

    Authors: Louis Potier, Renata Chequer, Ronan Roussel, Kamel Mohammedi, Souad Sismail, Agnès Hartemann, Chloé Amouyal, Michel Marre, Dominique Le Guludec and Fabien Hyafil
    Citation: Cardiovascular Diabetology 2018 17:11
  5. Statins are widely used for lipid lowering in patients with coronary artery disease (CAD), but increasing evidence indicates an association between statin use and new-onset of diabetes mellitus (NODM). Epicard...

    Authors: Jeehoon Kang, Young-Chan Kim, Jin Joo Park, Sehun Kim, Si-Hyuck Kang, Young Jin Cho, Yeonyee E. Yoon, Il-Young Oh, Chang-Hwan Yoon, Jung-Won Suh, Young-Seok Cho, Tae-Jin Youn, In-Ho Chae and Dong-Ju Choi
    Citation: Cardiovascular Diabetology 2018 17:10
  6. Drugs that inhibit dipeptidyl peptidase-4 (DPP-4) are conventionally regarded as incretin-based agents that signal through the glucagon-like peptide-1 (GLP-1) receptor. However, inhibition of DPP-4 also potent...

    Authors: Milton Packer
    Citation: Cardiovascular Diabetology 2018 17:9
  7. Incretin-based therapies are used in the treatment of type 2 diabetes mellitus (T2DM) and obesity. We investigated the changes in arterial stiffness and left ventricular (LV) myocardial deformation after 6-mon...

    Authors: Vaia Lambadiari, George Pavlidis, Foteini Kousathana, Maria Varoudi, Dimitrios Vlastos, Eirini Maratou, Dimitrios Georgiou, Ioanna Andreadou, John Parissis, Helen Triantafyllidi, John Lekakis, Efstathios Iliodromitis, George Dimitriadis and Ignatios Ikonomidis
    Citation: Cardiovascular Diabetology 2018 17:8
  8. Cardiac magnetic resonance (CMR) T1 mapping and tissue-tracking strain analysis are useful quantitative techniques that can characterize myocardial tissue and mechanical alterations, respectively, in patients ...

    Authors: Yukun Cao, Wenjuan Zeng, Yue Cui, Xiangchuang Kong, Miao Wang, Jie Yu, Shan Zhang, Jing Song, Xu Yan, Andreas Greiser and Heshui Shi
    Citation: Cardiovascular Diabetology 2018 17:7
  9. Glycosuria produced by sodium–glucose co-transporter-2 (SGLT-2) inhibitors is associated with weight loss. SGLT-2 inhibitors reportedly might reduce the occurrence of cardiovascular events. Epicardial adipose ...

    Authors: Takao Sato, Yoshifusa Aizawa, Sho Yuasa, Shohei Kishi, Koichi Fuse, Satoshi Fujita, Yoshio Ikeda, Hitoshi Kitazawa, Minoru Takahashi, Masahito Sato and Masaaki Okabe
    Citation: Cardiovascular Diabetology 2018 17:6
  10. Sodium tissue content by 23Na magnetic resonance imaging (Na-MRI) has been validated in experimental and human studies. SGLT-2 inhibition blocks the reabsorption of glucose and of sodium in the proximal tubular c...

    Authors: M. V. Karg, A. Bosch, D. Kannenkeril, K. Striepe, C. Ott, M. P. Schneider, F. Boemke-Zelch, P. Linz, A. M. Nagel, J. Titze, M. Uder and R. E. Schmieder
    Citation: Cardiovascular Diabetology 2018 17:5
  11. Data on the influence of glycemic status on the progression of coronary calcification, an important marker for future adverse cardiovascular events, are limited.

    Authors: Ki-Bum Won, Donghee Han, Ji Hyun Lee, Sang-Eun Lee, Ji Min Sung, Su-Yeon Choi, Eun Ju Chun, Sung Hak Park, Hae-Won Han, Jidong Sung, Hae Ok Jung and Hyuk-Jae Chang
    Citation: Cardiovascular Diabetology 2018 17:4
  12. A recent study found that among individuals with a preserved left ventricular ejection fraction ≥ 55%, global longitudinal strain was significantly lower in overweight patients (i.e., body mass index ≥ 25 kg/m2) ...

    Authors: Katrine Dina Musaeus and Manan Pareek
    Citation: Cardiovascular Diabetology 2018 17:3
  13. The cardiovascular safety and efficacy of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) ar...

    Authors: Yan-Rong Li, Sung-Sheng Tsai, Dong-Yi Chen, Szu-Tah Chen, Jui-Hung Sun, Hung-Yu Chang, Miaw-Jene Liou and Tien-Hsing Chen
    Citation: Cardiovascular Diabetology 2018 17:2
  14. NG-Methylation of l-arginine (Arg) residues in certain proteins by protein arginine methyltransferases and subsequent proteolysis yields NG-monomethyl-l-arginine (MMA), NG,NG-dimethyl-l-arginine (asymmetric dimet...

    Authors: Dimitrios Tsikas, Alexander Bollenbach, Erik Hanff and Arslan Arinc Kayacelebi
    Citation: Cardiovascular Diabetology 2018 17:1
  15. Attenuated increases in ventricular stroke volume during exercise are common in type 2 diabetes and contribute to reduced aerobic capacity. The purpose of this study was to determine whether impaired ventricul...

    Authors: Genevieve A. Wilson, Gerard T. Wilkins, Jim D. Cotter, Regis R. Lamberts, Sudish Lal and James C. Baldi
    Citation: Cardiovascular Diabetology 2017 16:160
  16. Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF ass...

    Authors: Chia-Yu Chang, Yung-Hsin Yeh, Yi-Hsin Chan, Jia-Rou Liu, Shang-Hung Chang, Hsin-Fu Lee, Lung-Sheng Wu, Kun-Chi Yen, Chi-Tai Kuo and Lai-Chu See
    Citation: Cardiovascular Diabetology 2017 16:159
  17. Elevated levels of low-density lipoprotein cholesterol (LDL-C) and glycosylated hemoglobin (HbA1c) are risk factors for cardiovascular complications. This study evaluated LDL-C goal attainment in Russian clini...

    Authors: Sergey Boytsov, Natalia Logunova and Yunona Khomitskaya
    Citation: Cardiovascular Diabetology 2017 16:158
  18. Hyperglycemia is associated with increased morbidity and mortality in patients with an acute myocardial infarction (AMI). We evaluated whether complications after AMI are associated with absolute or relative g...

    Authors: Tien F. Lee, Morton G. Burt, Leonie K. Heilbronn, Arduino A. Mangoni, Vincent W. Wong, Mark McLean and N. Wah Cheung
    Citation: Cardiovascular Diabetology 2017 16:157
  19. Coronary atherosclerosis progresses faster in patients with diabetes mellitus (DM) and causes higher morbidity and mortality in such patients compared to non-diabetics ones (non-DM). We quantify changes in pla...

    Authors: Tomas Kovarnik, Zhi Chen, Gary S. Mintz, Andreas Wahle, Kristyna Bayerova, Ales Kral, Martin Chval, Karel Kopriva, John Lopez, Milan Sonka and Ales Linhart
    Citation: Cardiovascular Diabetology 2017 16:156
  20. Cardiovascular disease, predominantly ischemic heart disease (IHD), is the leading cause of death in diabetes mellitus (DM). In addition to eliciting cardiomyopathy, DM induces a ‘wicked triumvirate’: (i) incr...

    Authors: Jake Russell, Eugene F. Du Toit, Jason N. Peart, Hemal H. Patel and John P. Headrick
    Citation: Cardiovascular Diabetology 2017 16:155
  21. The potential of anti-aging effect of DPP-4 inhibitors is unknown. This study was performed to determine whether linagliptin, a DPP-4 inhibitor, could protect against premature aging in klotho−/− mice.

    Authors: Yu Hasegawa, Kenyu Hayashi, Yushin Takemoto, Cao Cheng, Koki Takane, Bowen Lin, Yoshihiro Komohara and Shokei Kim-Mitsuyama
    Citation: Cardiovascular Diabetology 2017 16:154
  22. Biomarkers of inflammation and adiponectin are associated with cardiovascular autonomic neuropathy (CAN) in cross-sectional studies, but prospective data are scarce. This study aimed to assess the associations...

    Authors: Christian Stevns Hansen, Dorte Vistisen, Marit Eika Jørgensen, Daniel R. Witte, Eric J. Brunner, Adam G. Tabák, Mika Kivimäki, Michael Roden, Marek Malik and Christian Herder
    Citation: Cardiovascular Diabetology 2017 16:153
  23. Patients with type 2 diabetes (T2DM) are at high risk for cardiovascular events, which usually arise from the rupture of a vulnerable coronary plaque. The minimal fibrous cap thickness (FCT) overlying a necrot...

    Authors: Andrea Milzi, Mathias Burgmaier, Kathrin Burgmaier, Martin Hellmich, Nikolaus Marx and Sebastian Reith
    Citation: Cardiovascular Diabetology 2017 16:152
  24. Diabetes mellitus is considered an important risk factor for cardiovascular diseases. High hemoglobin A1c (HbA1c) levels, which indicate poor glycemic control, have been associated with occurrence of cardiovas...

    Authors: Shohei Ouchi, Kazunori Shimada, Tetsuro Miyazaki, Shuhei Takahashi, Yurina Sugita, Megumi Shimizu, Azusa Murata, Tomoyasu Kadoguchi, Takao Kato, Tatsuro Aikawa, Shoko Suda, Eiryu Sai, Masaru Hiki, Hiroshi Iwata, Takatoshi Kasai, Katsumi Miyauchi…
    Citation: Cardiovascular Diabetology 2017 16:151
  25. Following publication of the original article [1], the authors identified a number of errors. In Result (P.3), Table 1 (P.4), Table 5 (P.9) and Supplementary Table 1, the correct unit for adiponectin was μg/mL. I...

    Authors: Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi, Saki Yamamoto, Masako Tomoyasu, Anna Osamura, Makoto Ohara, Takeshi Yamamoto, Yasuki Ito and Tsutomu Hirano
    Citation: Cardiovascular Diabetology 2017 16:149

    The original article was published in Cardiovascular Diabetology 2017 16:8

  26. Hypoglycemia is associated with increased mortality rate in patients with diabetes. The underlying mechanisms may involve reduced myocardial tolerance to ischemia and reperfusion (IR) or reduced capacity for i...

    Authors: Kim B. Pælestik, Nichlas R. Jespersen, Rebekka V. Jensen, Jacob Johnsen, Hans Erik Bøtker and Steen B. Kristiansen
    Citation: Cardiovascular Diabetology 2017 16:148
  27. Irisin is a hormone released mainly from skeletal muscle after exercise which increases adipose tissue energy expenditure. Adipocytes can also release irisin after exercise, acting as a local adipokine to indu...

    Authors: Karan S. Rana, Chathyan Pararasa, Islam Afzal, David A. Nagel, Eric J. Hill, Clifford J. Bailey, Helen R. Griffiths, Ioannis Kyrou, Harpal S. Randeva, Srikanth Bellary and James E. Brown
    Citation: Cardiovascular Diabetology 2017 16:147
  28. The cardiovascular benefits of statins have been proven, but their effect on circulation in small vessels has not been examined fully. We investigated the effect of 20 mg rosuvastatin on biomarkers, including ...

    Authors: Kyoung Min Kim, Kyong Yeun Jung, Han Mi Yun, Seo Young Lee, Tae Jung Oh, Hak Chul Jang and Soo Lim
    Citation: Cardiovascular Diabetology 2017 16:146

    The Retraction Note to this article has been published in Cardiovascular Diabetology 2019 18:32

  29. Coexistence of left ventricular (LV) longitudinal myocardial systolic dysfunction with LV diastolic dysfunction could lead to heart failure with preserved ejection fraction (HFpEF). Diabetes mellitus (DM) is k...

    Authors: Makiko Suto, Hidekazu Tanaka, Yasuhide Mochizuki, Jun Mukai, Hiroki Takada, Fumitaka Soga, Kumiko Dokuni, Yutaka Hatani, Keiko Hatazawa, Hiroki Matsuzoe, Hiroyuki Sano, Hiroyuki Shimoura, Junichi Ooka, Kensuke Matsumoto, Yushi Hirota, Wataru Ogawa…
    Citation: Cardiovascular Diabetology 2017 16:145
  30. Type 2 diabetes mellitus (T2DM) is strongly related to the in-hospital and short-term prognosis in patients with cardiovascular diseases needing surgical or invasive interventions. How T2DM might influence the...

    Authors: Manuel Mendez-Bailon, Noel Lorenzo-Villalba, Nuria Muñoz-Rivas, Jose Maria de Miguel-Yanes, Javier De Miguel-Diez, Josep Comín-Colet, Valentin Hernandez-Barrera, Rodrigo Jimenez-Garcia and Ana Lopez-de-Andres
    Citation: Cardiovascular Diabetology 2017 16:144
  31. Macrophages play a pivotal role in atherosclerotic plaque development. Recent evidence has suggested the glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide, can attenuate pro-inflammatory responses...

    Authors: Robyn Bruen, Sean Curley, Sarina Kajani, Daniel Crean, Marcella E. O’Reilly, Margaret B. Lucitt, Catherine G. Godson, Fiona C. McGillicuddy and Orina Belton
    Citation: Cardiovascular Diabetology 2017 16:143
  32. Diabetes mellitus is a risk factor for coronary artery disease and diabetic cardiomyopathy, and adversely impacts outcomes following coronary artery bypass grafting. Current treatments focus on macro-revascula...

    Authors: Masashi Kawamura, Michael J. Paulsen, Andrew B. Goldstone, Yasuhiro Shudo, Hanjay Wang, Amanda N. Steele, Lyndsay M. Stapleton, Bryan B. Edwards, Anahita Eskandari, Vi N. Truong, Kevin J. Jaatinen, Arnar B. Ingason, Shigeru Miyagawa, Yoshiki Sawa and Y. Joseph Woo
    Citation: Cardiovascular Diabetology 2017 16:142
  33. We have previously shown that many chronic, inflammatory diseases are accompanied, and possibly partly caused or exacerbated, by various coagulopathies, manifested as anomalous clots in the form of ‘dense matt...

    Authors: Etheresia Pretorius, Martin J. Page, Lize Engelbrecht, Graham C. Ellis and Douglas B. Kell
    Citation: Cardiovascular Diabetology 2017 16:141
  34. Pioglitazone (PIO), a thiazolidinediones drug, is a well-known anti-diabetic medicine, but its anti-atherosclerotic effects remain controversial. Thus it is important to investigate the effects of PIO on ather...

    Authors: Yuling Tian, Tao Chen, Yan Wu, Lin Yang, Lijun Wang, Xiaojuan Fan, Wei Zhang, Jiahao Feng, Hang Yu, Yanjie Yang, Juan Zhou, Zuyi Yuan and Yue Wu
    Citation: Cardiovascular Diabetology 2017 16:140
  35. Altered regulation of extracellular matrix (ECM) composition by matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs) may contribute to arterial stiffening. We investigated associ...

    Authors: Stijn A. Peeters, Lian Engelen, Jacqueline Buijs, Nish Chaturvedi, John H. Fuller, Anders Jorsal, Hans-Henrik Parving, Lise Tarnow, Simone Theilade, Peter Rossing, Casper G. Schalkwijk and Coen D. A. Stehouwer
    Citation: Cardiovascular Diabetology 2017 16:139
  36. Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardiovascular events in patients with type 2 diabetes through not fully elucidated mechanisms. Aim of this study was to inves...

    Authors: Anna Solini, Livia Giannini, Marta Seghieri, Edoardo Vitolo, Stefano Taddei, Lorenzo Ghiadoni and Rosa Maria Bruno
    Citation: Cardiovascular Diabetology 2017 16:138
  37. These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD...

    Authors: Guntram Schernthaner, Roger Lehmann, Martin Prázný, Leszek Czupryniak, Kristine Ducena, Peter Fasching, Andrej Janež, Avraham Karasik, Peter Kempler, Emil Martinka, Marina V. Shestakova, Lea Smirčić Duvnjak and Tsvetalina Tankova
    Citation: Cardiovascular Diabetology 2017 16:137
  38. This article was unintentionally published twice in this journal, by the same authors. The following should be considered the version of record and used for citation purposes: “Mehran Haidari, Wei Zhang, James...

    Authors: Mehran Haidari, Wei Zhang, James T. Willerson and Richard A. F. Dixon
    Citation: Cardiovascular Diabetology 2017 16:136

    The original article was published in Cardiovascular Diabetology 2014 13:112

  39. Following publication of the original article [1], author Antonio Ceriello requested that a correction be published in relation to his affiliations. His correct affiliations have been updated in this erratum. Thi...

    Authors: Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Stefano Genovese, Nebojsa Lalic, Jan Skra, Paul Valensi, Dario Rahelic and Antonio Ceriello
    Citation: Cardiovascular Diabetology 2017 16:135

    The original article was published in Cardiovascular Diabetology 2017 16:35

  40. Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone trea...

    Authors: Marit de Jong, H. Bart van der Worp, Yolanda van der Graaf, Frank L. J. Visseren and Jan Westerink
    Citation: Cardiovascular Diabetology 2017 16:134
  41. Previous studies have demonstrated that secreted frizzled-related protein 4 (SFRP4) is associated with impaired glucose and triglyceride metabolism in patients with stable coronary artery disease. In the prese...

    Authors: Qingwei Ji, Jianwei Zhang, Yu Du, Enjun Zhu, Zhijian Wang, Bin Que, Huangtai Miao, Shutian Shi, Xiuchuan Qin, Yingxin Zhao, Yujie Zhou, Fangjun Huang and Shaoping Nie
    Citation: Cardiovascular Diabetology 2017 16:133
  42. Functional properties of high density lipoproteins (HDL) are increasingly recognized to play a physiological role in atheroprotection. Type 2 diabetes mellitus (T2DM) is characterized by low HDL cholesterol, b...

    Authors: Sanam Ebtehaj, Eke G. Gruppen, Mojtaba Parvizi, Uwe J. F. Tietge and Robin P. F. Dullaart
    Citation: Cardiovascular Diabetology 2017 16:132
  43. Both the progression of diabetic kidney disease and increased glycemic variability play important roles in the pathogenesis of coronary plaque formation via inflammatory pathways in patients with type 2 diabet...

    Authors: Kentaro Kakuta, Kaoru Dohi, Miho Miyoshi, Takashi Yamanaka, Masaki Kawamura, Jun Masuda, Tairo Kurita, Toru Ogura, Norikazu Yamada, Yasuhiro Sumida and Masaaki Ito
    Citation: Cardiovascular Diabetology 2017 16:131
  44. Asymptomatic left ventricular (LV) dysfunction is highly prevalent in type 2 diabetes patients. Unlike the other hypoglycemic drugs, SGLT2 inhibitors have shown potential benefits for reducing cardiovascular d...

    Authors: Andrea Natali, Lorenzo Nesti, Iacopo Fabiani, Enrico Calogero and Vitantonio Di Bello
    Citation: Cardiovascular Diabetology 2017 16:130
  45. In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardi...

    Authors: Oliver Schnell, Lars Rydén, Eberhard Standl and Antonio Ceriello
    Citation: Cardiovascular Diabetology 2017 16:128

    The Correction to this article has been published in Cardiovascular Diabetology 2017 16:150

  46. We investigated whether glycated albumin (GA) and its variability are associated with cardiovascular autonomic neuropathy (CAN) and further compared their associations with glycated hemoglobin (HbA1c).

    Authors: Ji Eun Jun, Seung-Eun Lee, You-Bin Lee, Ji Yeon Ahn, Gyuri Kim, Sang-Man Jin, Kyu Yeon Hur, Moon-Kyu Lee and Jae Hyeon Kim
    Citation: Cardiovascular Diabetology 2017 16:127
  47. Diabetes mellitus has long been associated with cardiovascular events. Nevertheless, the higher burden of traditional cardiovascular risk factors reported in high-income countries is offset by a more widesprea...

    Authors: José M. de Miguel-Yanes, Rodrigo Jiménez-García, Valentín Hernández-Barrera, Manuel Méndez-Bailón, Javier de Miguel-Díez and Ana Lopez-de-Andrés
    Citation: Cardiovascular Diabetology 2017 16:126
  48. Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects in advanced atherosclerosis were not shown...

    Authors: Naoyuki Kitao, Hideaki Miyoshi, Tomoo Furumoto, Kota Ono, Hiroshi Nomoto, Aika Miya, Chiho Yamamoto, Atsushi Inoue, Kenichi Tsuchida, Naoki Manda, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura and Tatsuya Atsumi
    Citation: Cardiovascular Diabetology 2017 16:125

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 8.5
    5-year Journal Impact Factor: 8.9
    Source Normalized Impact per Paper (SNIP): 1.855
    SCImago Journal Rank (SJR): 2.621

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 56

    Usage 2023
    Downloads: 2,523,778
    Altmetric mentions: 3,115